0 CHECKOUT

Whole Exome Sequencing Market by Product, by Services, by Technology, by Application - Global Forecast to 2018

  • ID: 2924783
  • August 2014
  • Region: Global
  • 245 Pages
  • Markets and Markets
1 of 5
This global whole exome sequencing market was valued at $326.6 million in 2013 and is expected to grow at a CAGR of 22.0% from 2013 to 2018, to reach $884.1 million by 2018.

FEATURED COMPANIES

  • Ambry Genetics
  • Eurofins Genomics, Inc.
  • Genewiz, Inc.
  • Illumina, Inc.
  • Knome, Inc.
  • Macrogen, Inc.
  • MORE

Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018

Whole Exome Sequencing (WES) is next-generation technology used for strategically sequencing the coding region of the genome, i.e. the exon. The exome, which is the total of all exons of an organism, represents only 1–2% of the total genome and is actually converted into proteins after translation. It is responsible for the occurrence of nearly 85% of genetic diseases. Whole exome sequencing is widely used for identifying and determining genetic variants responsible for various diseases such as Miller Syndrome and Alzheimer’s disease.

The applications of whole exome sequencing (WES) technologies have witnessed growth in recent years, which can be primarily attributed to the availability of advanced systems as well as the low cost of conducting exome sequencing, as compared with that of whole genome sequencing. The technological advancement is evident from the number of improved versions of existing sequencers released in recent READ MORE >

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ambry Genetics
  • Eurofins Genomics, Inc.
  • Genewiz, Inc.
  • Illumina, Inc.
  • Knome, Inc.
  • Macrogen, Inc.
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Secondary Research
1.5.2 Primary Research
1.5.2.1 Key Data Points From Primary Sources
1.5.3 Market Size Estimation Methodology
1.5.4 Market Forecast
1.5.5 Market Data Validation and Data Triangulation
1.6 Assumptions

2 Executive Summary

3 Market Overview
3.1 Introduction
3.2 Market Dynamics
3.2.1 Drivers
3.2.1.1 the Low Cost and High Speed of the Wes Technology to Drive the Growth of the Market
3.2.1.2 Increasing Number of New Scientific Applications to Fuel the Market Growth
3.2.1.3 Adoption of Wes Technology By New Consumers to Propel the Market Growth
3.2.1.4 Global Alliances Amongst Leading Research Institutes to Trigger Drug Discovery
3.2.1.5 Entry of New Players Is Propelling the Growth of the Wes Market
3.2.2 Restraints
3.2.2.1 Need for Skilled Professionals
3.2.2.2 High Reliability on Grants to Restrict Growth
3.2.2.3 Ethical and Legal Issues Related to Whole Exome Sequencing
3.2.3 Opportunities
3.2.3.1 Personalized Medicine to Fuel the Demand for Wes Technology
3.3 Market Share Analysis
3.3.1 Whole Exome Sequencing Products Market, By Key Player
3.3.2 WES Services Market, By Key Player

4 Whole Exome Sequencing Market, By Products and Services
4.1 Introduction
4.2 Systems
4.2.1 Hiseq Series
4.2.1.1 Hiseq 2500 and Hiseq 1500
4.2.2 Miseq
4.2.3 ION torrent Platforms
4.2.3.1 ION PGM and ION Proton
4.3 Kits
4.3.1 Introduction
4.3.2 DNA Fragmentation, End Repair, A-Tailing, and Size Selection Kits
4.3.3 Library Preparation Kits
4.3.4 Target Enrichment Kits
4.4 Services
4.4.1 Introduction
4.4.2 Sequencing Services Market
4.4.3 Data Analysis (Bioinformatics) Services
4.4.4 Other Services

5 Global Whole Exome Sequencing Market, By Technology
5.1 Introduction
5.2 Sequencing By Synthesis (SBS)
5.2.1 Technology
5.2.2 Advantages
5.2.3 Challenges
5.2.4 Applications
5.2.5 Platforms
5.3 ION Semiconductor Sequencing
5.3.1 Technology
5.3.2 Advantages
5.3.3 Limitations
5.3.4 Applications
5.3.5 Platforms
5.4 Other Technologies
5.4.1 Sequencing By Ligation (SBL)
5.4.1.1 Technology
5.4.1.2 Advantages
5.4.1.3 Limitations
5.4.1.4 Applications
5.4.2 Pyrosequencing
5.4.2.1 Technology
5.4.2.2 Advantages
5.4.2.3 Applications

6 Whole Exome Sequencing Market, By Application
6.1 Introduction
6.2 Diagnostics
6.2.1 Cancer Diagnostics
6.2.2 Monogenic (Mendelian) Disorders
6.2.3 Monogenic Types of Diabetes
6.2.4 Other Diagnostic Applications
6.2.4.1 Common Diseases and Complex Disorders
6.2.4.2 Movement Disorders
6.2.4.3 Hiv
6.3 Drug Discovery and Development
6.4 Personalized Medicine
6.5 Agriculture & Animal Research
6.6 Other Applications

7 Global Wholeexome Sequencing Market, By End User
7.1 End Users
7.2 Introduction
7.2.1 Research Centers and Academic & Government Institutes
7.2.2 Hospitals and Clinics
7.2.3 Pharmaceutical & Biotechnology Companies
7.2.4 Other End Users

8 Global Whole Exome Sequencing Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 Increasing Use of Whole Exome Sequencing for Diagnosis of Rare Diseases Propels the Market Growth
8.2.2 Government Funds for Exome Sequencing to Boost the Market
8.2.3 Favorable Initiatives By the Canadian Government to Trigger Wes Market in the Country
8.2.4 Conferences & Annual Meetings to Create Awareness About Wes Technologies
8.3 Europe
8.3.1 Investment in Rare Disease Research Likely to Boost the Wes Market in Europe
8.3.2 Belgium to Contribute Substantially to Market Growth in Europe
8.3.3 Increasing Funding for Molecular Diagnostics in Europe Is Likely to Propel the Growth of the Wes Market
8.3.4 Conferences & Meetings Hosted in Europe to Fuel the Market Growth
8.4 Asia
8.4.1 Asian Countries Are Increasingly Focusing on Research in Wes
8.4.2 Strategic Expansions and Aquisitions By Key Players in China to Boost the Market
8.4.3 Regular Funding From Indian Government, An Impetus to the Wes Market
8.4.4 Large Number of Conferences and Symposia in Asia to Drive Market Growth
8.5 Rest of the World (ROW)
8.5.1 Bioinformatics and Biotechnology Research in Latin America to Propel the Growth of the Market
8.5.2 Genomic & Proteomic Research in Australia to Drive the Growth of the Market
8.5.3 Flourishing Biotechnology & Pharmaceutical Markets in Brazil to Bolster the Growth of the Market

9 Competitive Landscape
9.1 Introduction
9.2 Agreements, Partnerships, & Collaborations
9.3 New Product Launches
9.4 Expansions
9.5 Acquisitions
9.6 Others

10 Company Profiles
10.1 Illumina, Inc.
10.1.1 Company Snapshot
10.1.2 Financial Overview
10.1.3 Products and Services
10.1.4 Key Strategies
10.1.5 Recent Developments
10.1.6 SWOT
10.1.7 MNM View
10.2 Thermo Fisher Scientific, Inc.
10.2.1 Company Snapshot
10.2.2 Financial Overview
10.2.3 Product Portfolio
10.2.4 Key Strategies
10.2.5 Recent Developments
10.2.6 SWOT
10.2.7 MNM View
10.3 Beijing Genomics Institute (Bgi)
10.3.1 Company Snapshot
10.3.2 Financial Overview
10.3.3 Services
10.3.4 Key Strategies
10.3.5 Recent Developments
10.3.6 SWOT
10.3.7 MNM View
10.4 Macrogen, Inc.
10.4.1 Company Snapshot
10.4.2 Financial Overview
10.4.3 Services
10.4.4 Key Strategy
10.4.5 Recent Developments
10.4.6 SWOT
10.4.7 MNM View
10.5 Eurofins Genomics, Inc.
10.5.1 Company Snapshot
10.5.2 Financial Overview
10.5.3 Services
10.5.4 Key Strategies
10.5.5 Recent Developments
10.5.6 SWOT
10.5.7 MNM View
10.6 Agilent Technologies, Inc.
10.6.1 Company Snapshot
10.6.2 Financial Overview
10.6.3 Products and Services
10.6.4 Key Strategies
10.6.5 Recent Developments
10.7 Ambry Genetics
10.7.1 Company Snapshot
10.7.2 Financial Overview
10.7.3 Services
10.7.4 Key Strategy
10.7.5 Recent Developments
10.8 Genewiz, Inc.
10.8.1 Company Snapshot
10.8.2 Financial Overview
10.8.3 Services
10.8.4 Key Strategy
10.8.5 Recent Developments
10.9 Knome, Inc.
10.9.1 Company Snapshot
10.9.2 Financial Overview
10.9.3 Products and Services
10.9.4 Key Strategies
10.9.5 Recent Developments
10.10 Roche Nimblegen, Inc.
10.10.1 Company Snapshot
10.10.2 Financial Overview
10.10.3 Products and Services
10.10.4 Key Strategy
10.10.5 Recent Developments
10.11 Sengenics
10.11.1 Company Snapshot
10.11.2 Financial Overview
10.11.3 Services
10.11.4 Key Strategy
10.11.5 Recent Developments

List of Tables (80 Tables)

Table 1 Price Comparison for Whole Genome and Whole Exome Sequencing
Table 2 Employee Split for the Year 2013, By Geography
Table 3 Global Whole Exome Sequencing Market, By Products and Services, 2011–2018 ($Million)
Table 4 Global WES Products Market, By Type, 2011–2018 ($Million)
Table 5 Global Whole Exome Sequencing Products Market, By Region, 2011–2018 ($Million)
Table 6 Technical Specifications of Sequencing Systems
Table 7 Global WES Systems Market, By Region, 2011–2018 ($Million)
Table 8 Table: Comparison Between Sequencing Kits
Table 9 Global Whole Exome Sequencing Kits Market, By Type, 2011–2018 ($Million)
Table 10 Global WES Kits Market, By Region, 2011–2018 ($Million)
Table 11 DNA Fragmentation, End Repair, A-Telling, and Size Selection Kits Market, By Region, 2011–2018 ($Million)
Table 12 Whole Exome Sequencing Market Size for Library Preparation Kits, By Region, 2011–2018 ($Million)
Table 13 Market Size for Target Enrichment Kits, By Region, 2011–2018 ($Million)
Table 14 Global Whole Exome Sequencing Services Market, By Type, 2011–2018 ($Million)
Table 15 Global WES Services Market, By Region, 2011–2018 ($Million)
Table 16 Market Size for Sequencing Services, By Geography, 2011–2018 ($Million)
Table 17 Market Size for Data Analysis Services, By Region, 2011–2018 ($Million)
Table 18 Other Services Market, By Region, 2011–2018 ($Million)
Table 19 Global Market Size, By Technology, 2011–2018 ($Million)
Table 20 Market Size for Sequencing By Synthesis Technology, By Region, 2011–2018 ($Million)
Table 21 Market Size for ION Semiconductor Sequencing Technology, By Region, 2011–2018 ($Million)
Table 22 Market Size for Other Sequencing Technologies, By Region, 2011–2018 ($Million)
Table 23 Global Whole Exome Sequencing Market Size, By Application, 2011–2018 ($Million)
Table 24 Market Size for Diagnostic Applications, By Type, 2011–2018 ($Million)
Table 25 Market Size for Diagnostic Applications, By Region, 2011–2018 ($Million)
Table 26 Market Size for Cancer Diagnostics, By Region, 2011–2018 ($Million)
Table 27 Market Size for Monogenic Disorder Diagnostics, By Region, 2011–2018 ($Million)
Table 28 Market Size for Monogenic Types of Diabetes, By Region, 2011–2018 ($Million)
Table 29 Market Size for Other Diagnostic Applications, By Region, 2011–2018 ($Million)
Table 30 Market Size for Drug Discovery and Development, By Region, 2011–2018 ($Million)
Table 31 Market Size for Personalized Medicine, By Region, 2011–2018 ($Million)
Table 32 Market Size for Agriculture and Animal Research, By Region, 2011–2018 ($Million)
Table 33 Market Size for Other Applications, By Region, 2011–2018 ($Million)
Table 34 Global Whole Exome Sequencing Market Size, By End User, 2011–2018 ($Million)
Table 35 Market Size for Research Centers and Academic & Government Institutes, By Region, 2011–2018 ($Million)
Table 36 Market Size for Hospitals and Clinics, By Region, 2011–2018 ($Million)
Table 37 Market Size for Pharmaceutical and Biotechnology Companies, By Region, 2011–2018 ($Million)
Table 38 Market Size forother End Users, By Region, 2011–2018 ($Million)
Table 39 Market Size, By Region, 2011–2018 ($Million)
Table 40 Conferences/Meetings/forums/Workshops in the U.S., 2014
Table 41 North America: Whole Exome Sequencing Market Size, By Technology, 2011–2018 ($Million)
Table 42 North America: Market Size, By Products and Services, 2011–2018 ($Million)
Table 43 North America: Whole Exome Sequencing Products Market Size, By Type, 2011–2018 ($Million)
Table 44 North America: WES Kits Market Size, By Type, 2011–2018 ($Million)
Table 45 North America: WES Services Market Size, By Type, 2011–2018 ($Million)
Table 46 North America: Market Size, By Application, 2011–2018 ($Million)
Table 47 North America: Market Size for Diagnostic Applications, By Type, 2011–2018 ($Million)
Table 48 North America: Market Size, By End User, 2011–2018 ($Million)
Table 49 Conferences/Meetings/Forums/Workshops in Europe, 2014
Table 50 Europe: Whole Exome Sequencing Market Size, By Technology, 2011–2018 ($Million)
Table 51 Europe: Market Size, By Products and Services, 2011–2018 ($Million)
Table 52 Europe: Whole Exome Sequencing Products Market Size, By Type, 2011–2018 ($Million)
Table 53 Europe: WES Kits Market Size, By Type, 2011–2018 ($Million)
Table 54 Europe: WES Services Market Size, By Type, 2011–2018 ($Million)
Table 55 Europe: Market Size, Application, 2011–2018 ($Million)
Table 56 Europe: Market Size for Diagnostic Applications, By Type, 2011–2018 ($Million)
Table 57 Europe: Market Size, By End User, 2011–2018 ($Million)
Table 58 Conferences/Meetings/Forums/Workshops in Asia, 2014
Table 59 Asia: Whole Exome Sequencing Market Size, By Technology, 2011–2018 ($Million)
Table 60 Asia: Market Size, By Products and Services, 2011–2018 ($Million)
Table 61 Asia: WES Products Market Size, By Type, 2011–2018 ($Million)
Table 62 Asia: WES Kits Market Size, By Type, 2011–2018 ($Million)
Table 63 Asia: WES Services Market Size, By Type, 2011–2018 ($Million)
Table 64 Asia: Market Size, Application, 2011–2018 ($Million)
Table 65 Asia: Market Size for Diagnostic Applications, By Type, 2011–2018 ($Million)
Table 66 Asia: Market Size, By End User, 2011–2018 ($Million)
Table 67 ROW: Whole Exome Sequencing Market Size, By Technology, 2011–2018 ($Million)
Table 68 ROW: Market Size, By Products and Services, 2011–2018 ($Million)
Table 69 ROW: Whole Exome Sequencing Products Market Size, By Type, 2011–2018 ($Million)
Table 70 ROW: Whole Exome Sequencing Kits Market Size, By Type, 2011–2018 ($Million)
Table 71 ROW: WES Services Market Size, By Type, 2011–2018 ($Million)
Table 72 ROW: Market Size, By Application, 2011–2018 ($Million)
Table 73 ROW: Market Size for Diagnostic Applications, By Type, 2011–2018 ($Million)
Table 74 ROW: Market Size, By End User, 2011–2018 ($Million)
Table 75 Agreement, Partnerships, & Collaborations, 2011–2014
Table 76 Key Players Focusing on New Product Launches, 2011–2014
Table 77 New Product Launches, 2011–2014
Table 78 Expansions, 2011–2013
Table 79 Acquisitions, 2011–2014
Table 80 Others, 2011–2014

List of Figures (26 Figures)

Figure 1 Research Methodology
Figure 2 Sampling Frame: Primary Research
Figure 3 Market Size Estimation Methodology (1/3)
Figure 4 Market Size Estimation Methodology (2/3)
Figure 5 Market Size Estimation Methodology (3/3)
Figure 6 Market Sizing ($Value Analysis)
Figure 7 Market Share Assessment
Figure 8 Market Forecasting Model
Figure 9 Data Triangulation Methodology
Figure 10 Global Market Size, By Products and Services (2013–2018)
Figure 11 Global Market Size, By Geography, 2013 ($Million)
Figure 12 Market Dynamics
Figure 13 Whole Exome Sequencing Products Market Share, By Key Player
Figure 14 Whole Exome Sequencing Products Market Share, By Key Player
Figure 15 Market Segmentation
Figure 16 Commonly Available Sequencing Kits
Figure 17 DNA Fragmentation, End Repair, A-Tailing, and Size Selection Kits Workfolw
Figure 18 Wes Technology Market Segmentation
Figure 19 Market, By Application
Figure 20 Market, By End User
Figure 21 Geographic Split for Whole Exome Sequencing Market, By Products and Services, 2013 Vs. 2018 ($Million)
Figure 22 Global Market: Key Growth Strategies, 2011–2014
Figure 23 Key Players Focusing on Agreements, Partnerships, & Collaborations, 2011–2014
Figure 24 Key Players Focusing on Expansions, 2011–2014
Figure 25 Key Players Focusing on Acquisitions, 2011–2014
Figure 26 Key Players Focusing on Other Strategies, 2011–2014

Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Ambry Genetics
  • Eurofins Genomics, Inc.
  • Genewiz, Inc.
  • Illumina, Inc.
  • Knome, Inc.
  • Macrogen, Inc.
  • MORE

Advances in DNA sequencing have transformed genomics and paved the way for whole exome sequencing in research. Whole exome sequencing is cost-efficient and quick, as compared to whole-genome sequencing. Sequencing the exome is also considered more effective, as exons possess 85% of disease traits. Thus, WES systems, kits, and services have seen increased adoption by researchers as they not only simplify work but also save time.

Technological advancements in sequencing systems, global alliances amongst leading research institutes to boost drug discovery, and an increase in life science and R&D expenditure are the key factors that are expected to drive the growth of this market. Primary factors that are restraining the growth of this market include high instrument costs, the need for skilled professionals, and high reliance on grants and funds.

The global whole exome sequencing market is categorized into five broad segments, namely, products and services, technologies, applications, end users, and geography. The global WES products and services market, by products, comprises systems and kits. The kits market is further segmented into DNA fragmentation, end repair, A-tailing, size selection kits, library preparation kits, and target enrichment kits. The WES products and services market, by services, comprises sequencing and data analysis services. The services market accounted for the largest share of the global WES products and services market in 2013.

The whole exome sequencing market, by applications, includes diagnostics, drug discovery and development, personalized medicine, and animal and plant research. In 2013, the diagnostics market held the largest share of the global WES applications market. The market, by end users, comprises research centers, academic and government institutions, hospitals and clinics, and pharmaceutical and biotech companies, among others. In 2013, research centers and academic and government institutions accounted for the largest share of the global market, by end users. On the basis of geography, this market is classified into four regions, namely, North America, Europe, Asia and Rest of the World (RoW).

This global whole exome sequencing market was valued at $326.6 million in 2013 and is expected to grow at a CAGR of 22.0% from 2013 to 2018, to reach $884.1 million by 2018. The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). North America is expected to maintain its leadership in the market in the coming years. Growth in the North American market is likely to be driven by factors such as the increasing use of exome sequencing in rare disease research, increased government funding, and large number of sequencing-related conferences and annual meetings hosted by the U.S.

The major players in the global whole exome sequencing market include Illumina, Inc. (U.S.) Life Technologies (acquired by Thermo Fisher Scientific, Inc.) (U.S.), Roche NimbleGen, Inc. (U.S.), Agilent Technologies (U.S.), BGI (Beijing Genomics Institute, China), Eurofins Genomics, Inc. (Germany), Sengenics (U.S.), GENEWIZ, Inc. (U.S.), Knome, Inc. (U.S.), Macrogen, Inc. (South Korea), and Ambry Genetics (U.S.), among others.

Exteneded Description

Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018

Whole Exome Sequencing (WES) is next-generation technology used for strategically sequencing the coding region of the genome, i.e. the exon. The exome, which is the total of all exons of an organism, represents only 1–2% of the total genome and is actually converted into proteins after translation. It is responsible for the occurrence of nearly 85% of genetic diseases. Whole exome sequencing is widely used for identifying and determining genetic variants responsible for various diseases such as Miller Syndrome and Alzheimer’s disease.

The applications of whole exome sequencing (WES) technologies have witnessed growth in recent years, which can be primarily attributed to the availability of advanced systems as well as the low cost of conducting exome sequencing, as compared with that of whole genome sequencing. The technological advancement is evident from the number of improved versions of existing sequencers released in recent years. For instance, in January 2014, the leading player in the whole exome sequencing market, Illumina, Inc. (U.S.), launched its NextSeq 500 System, which combines high-throughput performance with an affordable desktop form factor. This system is expected to enable researchers to perform sequencing in less than a day.

The major factors driving the growth of this market include its low cost and high speed, increase in applications areas for exome sequencing technologies, global alliances amongst leading research institutes to boost drug discovery, and the entry of new players in the whole-exome sequencing market. However, the high cost of instruments, the need for skilled professionals and high reliability on grants are hindering the market’s growth.

The services segment has the largest share of the global whole exome sequencing market, since it has a variety of applications in all areas, including diagnostics, drug discovery and development, personalized medicine, and agriculture and animal research. Diagnostics emerged as the largest whole exome sequencing application, primarily because of an increase in the usage of exome sequencing technologies in cancer and rare disease research.

In the years to come, the whole exome sequencing market is expected to experience high growth in Asia, particularly in China and India. These countries will serve as new revenue pockets for whole exome sequencing products and services companies. High growth in these regions can be attributed to growth in the pharmaceutical and biotech industry and crop research, increased funding scenarios and collaborations with established market players. U.S. and Europe are witnessing steady growth owing to new applications in diagnostics, applied markets, and technological advancements in these regions. Rest of the world (RoW) includes regions such as Latin America, Africa, the Middle East, and Pacific countries, which have increased focus on research and gaining funds, thus increasing the potential for whole exome sequencing in these regions.

While the global whole exome sequencing products market witnesses low competitive intensity, competition is strong in the services market, with few big firms and many small companies in the fray offering similar services. These companies adopt various strategies (innovations, acquisitions, and geographic expansions) to increase their market shares and establish a strong foothold in the global market.

Reasons to Purchase:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

- Market Penetration: Comprehensive information on the product portfolios of and services offered by top players in the whole exome sequencing market. The report analyzes the whole exome sequencing market by products and services

- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the whole exome sequencing market

- Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes markets for various whole exome sequencing technologies and services across geographies

- Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the whole exome sequencing market

- Competitive Assessment: In-depth assessment of market shares, strategies, products and services, distribution networks, and manufacturing capabilities of leading players in the whole exome sequencing market

Note: Product cover images may vary from those shown
4 of 5

- Agilent Technologies, Inc.
- Ambry Genetics
- Beijing Genomics Institute (Bgi)
- Eurofins Genomics, Inc.
- Genewiz, Inc.
- Illumina, Inc.
- Knome, Inc.
- Macrogen, Inc.
- Roche Nimblegen, Inc.
- Sengenics
- Thermo Fisher Scientific, Inc.

Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Amgen Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Beckman Coulter, Inc.
  • Novartis AG
  • Baxter International Inc.